Gene expression profiling and genomic approaches for genome-wide identification of ERα binding regions, such as ChIP-chip and ChIP-seq, have allowed the identification of direct ERα targets in breast cancer cells (16–19) and in tumours (20). Here, ESR1 is linked to neoplasm.